Objectives: Surgery is the elective treatment for chest wall sarcoma. Local recurrence, varies from 7% (Pairolero) to 52% (King), and is normally determined by an inadequate surgical exeresis. The goal of this paper is to de ne a preoperative approach to study tumor margins. Methods: 19 patients with a chest wall sarcoma were routinely submitted to an Rx, CT, MRI, total body scintigraphy, and US evaluation. US was always performed by the same person with a Siemens Sonoline Omnia, employing a probe 5-13 Mhz, and performing a color-doppler evaluation of the lesion. The scan was done with the patient lying in the surgical position. Tumor lateral margins were identi ed and a line was marked out at 4 cm (safe oncological margin). Results: Histologically all the surgical specimen removed following the US margins revealed wide exeresis (Enneking classication). On the contrary CT scan and MRI showed a 27% underestimation and a 18% overestimation respectively of the tumor lateral margins. CT and MRI correctly evaluated in 94% of patients deep margins. US detected one or more micronodules in 4 out of 5 patients with local recurrence. Histologically they were all sarcoma nodules (mean diameter 3 mm). 18 patients were disease free at 24 months (4-9). One patient died due to cerebral and bone metastasis. Conclusions: US sensitivity (100%), speci city (98%), and accuracy (98%) in detecting chest wall involvement of lung cancer is well known since 10 years (Suzuki). Our results con rm the reliability of US also in the study of chest wall sarcomas super cial margins and micronodules. Objectives: Detecting the extension of local spread of soft tissue sarcoma (STS) is of utmost importance for adequate resection. However, even MRI fails in correctly describing tumor invasion to neurovascular bundles. We explored, whether high-resolution (intravascular ultrasound (IVUS) improves correct assessment of vascular in ltration. Methods: To qualify for enrollment, patients had to have a histologically con rmed STS with the tumor located close to and suspected to invade a neurovascular bundle. Twenty-eight patients (12 f, 16 m, age 30-72 yrs) were examined. Tumors were located in the retroperitoneum (n=4), groin (n=7), thigh (n=9), popliteal fossa (n=9), lower leg (n=2), and axilla (n=1). Typing: liposarcoma (n=8), leiomyos. (n=6), MFH (n=6), synovial (n=5), MPNST (n=3), alveolar (n=1), hemangiopericytoma (n=1). A 2.9F IVUS-catheter (12.5 MHz, Ultracross, Boston Scienti c Corp.) was inserted via a side branch of the vessels exposed distant to the tumor during resection. IVUS ndings were compared with intraoperative assessment and the resection specimen. Results: In 16 patients, the vessels were resected, while 2 patients underwent subadventitial dissection, and in 10 patients the vessels were left untouched. IVUS detected 13 cases of vessel-invasive sarcoma (true positives). There were two false positives and one false negative whereas in another 12 cases no invasion could be found (true negative). Sensitivity: 92.8%, Speci city: 85.7%, positive predictive value (PPV): 86.6%, negative predictive value (NPV): 92.3%. Conclusions: IVUS provides an excellent tool to assess vessel invasion of STS. It can be handled intraoperatively and by this way allows the surgeon to examine the region of interest exactly. Highresolution ultrasound might overcome some of the problems of local staging still being not solved by MRI. 
Objectives: FDG (2-18 uoro-2-deoxy-D-glucose) PET scanning is useful for oncologic staging and treatment assessment. We evaluated its role in patients with soft tissue sarcomas. Methods: 59 patients underwent 97 PET scans, 50 at initial staging, which included primary site MRI and chest CT. PET activity was scored as 0=normal, 1= minimal, 2=moderate, and 3= intense. PET results were compared with chest CT to assess sensitivity /speci city. Most patients underwent neoadjuvant radiation or chemoradiation followed 3-4 weeks later by surgery. Re-staging PET, MRI, and chest CT were performed 1-3 weeks after neoadjuvant therapy and PET activity in the primary site was correlated to residual tumor in the surgical specimen. Results: Increased activity was seen at the primary site in 47 patients (94 %); median and mean activity scores were respectively 3 and 2.75. Two patients without PET activity had undergone excisional biopsy; a third had grade 1 liposarcoma. Sensitivity and speci city for PET for detecting lung metastases were 0.09 and 0.97 respectively, compared to 0.75 and 0.83 for chest CT. Positive and negative predictive values for PET were 0.50 and 0.77 compared to 0.56 and 0.92 for chest CT. On 39 re-staging PETs after neoadjuvant treatment, there was less activity, median score 2 and mean 2.18. No clear relationship emerged between residual activity and percent necrosis in the surgical specimen, although this has not yet been corrected for tumor grade. Conclusions: Soft tissue sarcomas are FDG avid at the primary site; activity decreases with neoadjuvant therapy. PET scanning is not useful for detection of lung metastases. Objectives: Patients with localized, high-grade soft tissue sarcomas (STS) are at signi cant risk of developing metastasis. Chemotherapy may reduce the risk of relapse; however, not all patients bene t from treatment. High-grade STS metabolize uorodeoxyglucose (FDG) to a greater extent than normal tissue which can be quanti ed by positron emission tomography (PET). We sought to determine whether the change in metabolic activity of STS in response to chemotherapy could serve as a surrogate measure for chemosensitivity and correlate with risk of disease recurrence. Methods: FDG-PET was performed prior to doxorubicin-based chemotherapy and prior to surgery. Patients were followed for a minimum of 2 years for recurrence of disease and death. Patient outcomes were analyzed by Kaplan-Meier analyses strati ed by change in FDG uptake, tumor grade, tumor size and pathologic response. Results: Thirty-eight patients with localized, high-grade STS were retrospectively studied. Seventeen patients remain free of tumor with a median follow-up of 3 years. Patients with a greater than 40% decrement in the maximum FDG uptake in STS in response to chemotherapy had a signi cantly lower risk of relapse and improved survival. Risk of relapse did not correlate with tumor grade, size or pathologic response to therapy. Conclusions: A change in the metabolism of FDG in response to chemotherapy may serve as a surrogate measure of chemotherapy sensitivity in high-grade soft tissue sarcomas. Patients with a large decrement in FDG uptake in response to doxorubicin-based therapy have a lower risk of disease recurrence and improved survival.
ateness of treatment, adequacy of surgery, and outcomes in terms of local control and overall survival. Results are strati ed for known risk factors for local control and survival (grade, depth and size) . Results: 260 patients were diagnosed as having STS over the 3 year period of whom 37% had the majority of treatment at the specialist centre under the care of 2 surgeons, whilst the other 63% were treated at a total of 38 different hospitals. Local recurrence rates were 20% at the specialist centre and 37% at the general hospitals. Overall survival was 58% at ve years and was related to grade, depth and size of tumour. Patients treated at the specialist centre had larger tumours (10.3 vs 7.3cm) with a higher proportion of deep and high grade tumours. Overall survival at the two centres was identical but when strati ed for known risk factors the survival rate was 1.6 times better at the specialist centre, this difference being especially obvious for Stage III tumours (p = 0.009). Objectives: When the surgical margin is positive after a planned wide excision, the aims of our study were to discern: 1)Is additional surgical excision or amputation warranted and, 2)If no additional surgery is done, is there a difference in overall survival (OS), continuous disease free survival (CDFS) or local recurrence (LRFS)? Methods: We performed a review of all patients meeting the inclusion criteria: non-metastatic soft tissue sarcomas (excluding rhabdo), extremity, trunk, retroperitoneum,treatment period 1975 -1997 @ Univ. Minnesota, age > 13 years.The treatment protocol was: attempted wide local excision, adjuvant radiation when closest margin is marginal, if positive margin identi ed on pathological analysis, further excision considered if technically possible depending upon size of surgical bed, anatomic location, patient's desires. Independent pathologist evaluation was performed with surgical margins de ned as: Negative (> 2 mm closest margin), Negative (< 2 mm closest margin), Positive-microscopic, Positivemacroscopic (gross tumor remaining), Inadvertent intraop contamination. Patients w/ a positive margin were then compared to those w/ a negative margin using standard survivorship analysis and Cox stepwise regression statistical methods. Results: The study cohort consisted of 413 patients (180 female, 233 male), mean age 51 yrs, with diagnoses liposarcoma (104), MFH (142), synovial sarcoma (44), other sarcoma (123). Tumor grades were low (50), intermediate (53), & high (254) . External beam radiation, mean dose 5688 cGy, was given preoperatively w/ postop boost to 112 (27%)patients & postoperatively only to 170 (41%) patients. No radiation was given to 131 (32%) patients. There was no difference in 5 yr OS between the positive vs. negative margin group, 76% vs. 61% (p=0.4), respectively. There was no difference in 5 yr CDFS between the positive vs. negative margin group, 61% vs. 68% (p=0.21), respectively. There was a statistical difference in 5 yr LRFS with the negative margin group being higher, 88% vs. 75% (p=0.02). The in uence of grade and margin revealed that for LRFS, positive margin was a risk factor (p=0.02) but grade was not. For both CDFS and OS, grade was a risk factor (p=0.01 and 0.04, respectively) but margin status was not. Among only low grade tumors there was no diff in OS, CDFS or LRFS comparing the positive vs. negative margin groups. Among only high grade tumors, there was a diff in LRFS (p=0.002) and CDFS (p=0.049) but not OS.
Conclusions

Conclusions:
We conclude a positive margin is associated with a higher risk of local relapse but not necessarily survival.When a positive surgical margin is sustained after a planned attempt at wide excision, additional surgery is not warranted for low grade tumors. For high grade tumors, CDFS but not OS is shorter when a positive margin occurs and therefore, it is uncertain if this is signi cant enough to warrant additional ablative surgery or amputation. Objectives: Soft tissue sarcomas are a heterogeneous group of malignancies of mesenchymal origin, the causes of which are unclear. In this study gene expression in leiomyosarcomas, myometrium, and uterine leiomyomas was examined. Methods: RNA was prepared and gene expression was determined at Gene Logic Inc. (Gaithersburg, MD) using Affymetrix GeneChip® U_95 arrays containing approximately 12,000 known genes and 48,000 ESTs. Gene expression analysis was performed with Gene Logic Gene Express® software. Differences in gene expression were quanti ed as the fold change in gene expression in leiomyosarcomas compared with normal myometrium, and uterine leiomyomas. Results: A number of genes were differentially expressed in these sample sets, and these genes were analyzed for their expression in a variety of other normal and diseased tissues. Some of the genes identi ed were over-expressed only in leiomyosarcomas among the tissues examined, and some were over-expressed in other tissues as well Conclusions: We conclude that differences in gene expression can be detected between leiomyosarcomas and uterine leiomyomas, and normal myometrium, and that these changes in gene expression may yield clues to the pathophysiology of this malignancy. Objectives: Osteosarcoma is the common primary malignant tumor of bone and is represented by a heterogenous group of lesions with diverse histopathology and clinical behavior. Hyaluronan (HA) has been thought to play signi cant roles in tumor progression. The aim of this study was to determine the differential pattern of expression of three hyaluronan synthase genes (HAS), that are responsible for the synthesis of HA in osteosarcomas. An additional goal was to analyze the effects of the inhibition of HAS genes by means of antisense oligonucleotides on the behavior of osteosarcoma cells. Methods: Total RNA was isolated from osteosarcoma cell lines, MG-63, which were cultured in monolayer, and subjected to competitive, quantitative RT-PCR to determine the mRNA copy numbers of HAS genes. Antisense oligonucleotides complimentary to the predominant HAS gene was transfected into osteosarcoma cells using a lipofection facilitator. The inhibition of HAS and HA expression was determined competitive RT-PCR and HA staining, respectively. Cell proliferation and invasion were analyzed by MTT assay and matrigel assay. Results: HAS-2 mRNA expression was 90-hold higher than HAS-3. Antisense oligos treatment for HAS-2 resulted in a 60% inhibition of HAS-2 mRNA levels and a remarkable decrease of HA accumulation around the cells.The suppression of HAS-2 also lead to the suppression of cell proliferation and invasion. Conclusions: HA inhibition via the down-regulation of HAS genes could control the behavior of osteosarcoma cells. Thus, the use of small antisense oligonucleotides to affect the selective inhibition of genes may provide a useful tool for the control of osteosarcomas. Objectives: The MET oncogene is activated in cell lines where it is ampli ed and over-expressed. Point mutations of its kinase domain leading to its activation have been found in families suffering from hereditary papillary renal cell carcinomas.We previously showed that the receptor is aberrantly expressed in a number of human osteosarcomas producing the ligand, suggesting that overexpression of MET receptor(s) might contribute to transformation of osteoprogenitor cells. Methods: To demonstrate the transforming potential of MET in human osteoblast-like cells(HOB-L), we constructed an ex-vivo model using primary cultures of HOB-L stably expressing wildtype or constitutively-active MET receptors by means of transduction with Lentiviral vectors in vitro. Results: All the wt-and mutant-MET-HOB-L clones showed a different morphology from parental HOB-L cells, namely a loss of contact-inhibition, proliferation at low serum concentrations and anchorage-independent growth.They formed colonies in soft agar, while the parental HOB-L cells did not. Tumorigenic potential of MET-HOB-L cells was assayed in immuno-compromised SCID mice. Two out 12 animals, which received wt-MET transduced osteoblast cells, developed tumor after a long latency. Nine out of 16 mice receiving mutated METexpressing osteoblast cells developed tumors in a shorter period. These tumors showed features of highly aggressive and undifferentiated osteosarcomas and carried integrated copies of the human MET. Conclusions: Over-expression of the MET oncogene activated by a point mutation makes the same cells not only transformed but also highly tumorigenic in immuno-compromised mice. These results show that over-expression of an activated tyrosine kinase suf ces to convert a primary human cell into a tumorigenic cell. Objectives: Activation of Met, the tyrosine kinase receptor for HGF/SF, induces downstream signalling pathways that trigger a number of cell functions, including proliferation, motility, invasiveness, and metastatic ability in a variety of neoplasms. Met is overexpressed in osteosarcoma, in association with an aggressive behavior of this tumor, both in vitro and in a clinical setting. We evaluated the ability of a natural alkaloid (K252a) which acts as a kinase inhibitor, by competing with the binding of ATP to the catalitic domain of Met, to interfere with the growth of human osteosarcoma cells, as a preliminary step toward the development of innovative therapeutic strategies for this tumor. Methods: We evaluated the level of Met expression by Western blotting in human osteosarcoma cell lines (U-2 OS, MG-63, Saos-2), that are representative of different levels of differentiation and aggressiveness of osteosarcoma. IC50 was analyzed at different concentrations of K252a (50-2000 ng/ml). Results: In osteosarcoma cells, the level of Met expression was associated with the ability of K252a to inhibit cell growth. In fact, the IC50 of K252a was 420 ng/ml in Saos-2, the more differentiated cell line with the lowest expression of Met, whereas it was 55.8 ng/ml in U-2 OS, the cell line with the lowest differentiated phenotype and the highest Met levels. Intermediate values (IC50, 190.7 ng/ml) were found in MG63. Conclusions: K252a is a potent inhibitor of proliferation of human osteosarcoma, and its effects are positively associated with the level of expression of Met, but inversely related to the differentiative status of the tumor. 
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, and 10 mM was administered to con uent TC-71 Ewing's sarcoma cells. At 6, 12, 24, and 72 hours following amifostine administration, MTT assays of cellular proliferation were performed. Clonogenicity assays of reproductive survival were also accomplished utilizing 0, 1, 5, and 10 mM concentrations of amifostine. Human monocytes were cultured from proximal femoral bone marrow aspirated during routine total hip procedures following IRB approved patient consent. These monocytes were similarly assayed following amifostine administration ANOVA was utilized with alpha 0.05. Results: Amifostine was acutely toxic to TC-71 Ewing's sarcoma cells at 5-10 mM, moderately toxic at 2 mM, and mild to moderately toxic at 0.5 and 1 mM as manifested by the MTT assays. Clonogenicity assays on the amifostine treated TC-71 cells conrmed the observations made with the MTT assay. By contrast, human monocytes exhibited a consistent increase in proliferation following amifostine administration. Conclusions: Amifostine has a cytotoxic effect on this Ewing's sarcoma cell line at clinically relevant concentrations (1-2 mM). By contrast, a proliferative effect of amifostine was observed in our human monocyte culture.These effects are promising and warrant further study of the putative differential radioprotective properties of amifostine in sarcomas. Objectives: To determine if amifostine given twice with each dose of ifosfamide or cyclophosphamide could provide protection from the myelotoxic effects of high dosage alkylator therapy, and prevent delay in the administration of chemotherapy. Methods: Patients (pts) less than 30 years of age with Ewing sarcoma metastatic at diagnosis and normal organ function were enrolled on a study of maximally intensi ed alkylator therapy without stem cell support. Cycles included alternating courses of ifosfamide (3.6 g/m2/day,for 5 days, week 6, then 2.8 g/m2/day,for 5 days, weeks 12 and 18), with etoposide (100 mg/m2/day,for 5 days) and vincristine (2 mg/m2), doxorubicin (75 mg/m2 over 48 hours) and cyclophosphamide (2.1 g/m2/day, for 2 days, weeks 9 and 15). Seventy pts were randomized to receive (36 pts), or not to receive (34 pts) amifostine. Topotecan(0.75 mg/m2/day,for 5 days) and cyclophosphamide (250 mg/m2/day,for 5 days) were administered to 23 patients on the amifostine arm (weeks 0, 3)and 16 on the no amifostine arm. The amifostine dosage administered was 825 mg/m2 15 minutes prior to, and 3 hours after the beginning of each dose of ifosfamide or cyclophosphamide, with premedications and precautions as previously described. Days ANC < 500/ul, days platelets < 50,000/ul and days between cycles were analyzed at weeks 6, 12 and 18 of therapy.
Results: There was no signi cant difference seen in any of the parameters studied: the mean number of days with platelet count < 50,000/ul:Wilcoxon rank sum test (WRS test, p-value: 0.29), the mean number of days with absolute neutrophil count < 500/ul: (WRS, p = 0.15), or the number of days until the next chemotherapy cycle: (p= 0.42). Toxicities attributable to amifostine included increased emesis, reversible hypotension, and asymptomatic hypocalcemia responding to calcium supplementation. Conclusions: In the dose and schedule used, amifostine did not provide myeloprotection from the toxicity of high dose alkylator therapy, and did not shorten the interval until the administration of the next chemotherapy cycle. Objectives: Doxorubicin and ifosfamide show signi cant activity in soft tissue sarcoma but have never been formally compared. We report a randomised Phase III comparison of single agent doxorubicin 75mg/m2 versus ifosfamide 3g/m2 over 4 hours daily for 3 days (Ifos 3*3) versus ifosfamide 9g/m2 over 72 hours by continuous infusion (Ifos 9) in patients with ASTS. Methods: Patients were strati ed by histological subtype, grade, metastatic site, performance status and institution. Response was evaluated after each 2 cycles and all responses independently reviewed. An interim analysis was carried out by an independent data monitoring committee after four years. Results: Between 1997 and Sept 2001, 322/760 patients were recruited. Groups were evenly divided by strati cation factors. Histological types were leiomyosarcoma 31.4%, liposarcoma 12.1%, synovial sarcoma 9.3%, others 46.2%. Toxicity was worse in both ifosfamide arms; grade 3 febrile neutropenia occurred in 8.3% doxorubicin patients, 20.7% Ifos 3*3 and 17% Ifos 9 patients. Response rates were: Doxorubicin 11% (CR 0.9%, PR 10.1%), Ifos 3*3 6.5% (CR 0.9%, PR 5.6%), Ifos 9 9.4% (CR 1.9%, PR 7.5%). With a median follow up of 14 months, there was no signi cant difference in progression free or overall survival in the three arms.The study hypothesis of a difference of 10% in PFS at 1 year was rejected and the trial stopped early on the advice of an independent data monitoring committee. Conclusions: For the majority of patients with ASTS for whom single agent chemotherapy is appropriate, doxorubicin 75mg/m2 remains the treatment of choice. Objectives: Dedifferentiated chondrosarcoma presents a very dif cult clinical problem. Long term survival is known to be poor, but a large clinical series has not been analyzed in the era of modern diagnostic and treatment modalities. Methods: A retrospective chart review of all cases of patients presenting with dedifferentiated chondrosarcoma at our institution from 1984-2000 was performed. This was done as an extension to a study published in 1986 prior to the era of modern chemotherapy.
Randomised
Expression of the
Results: There were 42 cases in 25 men and 17 women of average age 56 (range 24-83 years). MSTS grades at presentation were 5 IIA, 27 IIB, and 10 III. Three patients underwent biopsy only, 19 had limb sacri cing, and 20 had limb sparing procedures; surgical margins were intralesional in 3, marginal in 2, and wide in 20, and radical in 14. Twenty-seven patients received adjuvant therapy (22 chemotherapy only, 2 radiotherapy only, 3 combined therapy). Median survival was 8 months; 5-year survival was 7.1%. There was no statistical difference in survival between patients who did and did not receive chemotherapy, had wide versus radical resection, or had limb sparing versus sacri cing procedures. There were no statistically signi cant difference between patients treated prior to 1986 and those subsequently. Conclusions: Despite advances in diagnostic modalities, surgical treatments, and adjuvant therapies, dedifferentiated chondrosarcoma continues to carry a poor prognosis.The use of current adjuvant chemotherapy and its inherent risks and bene ts remains questionable in this population. Objectives: Thirty patients with desmoid tumors treated at our department with more than 20 years follow-up (mean 28 years) were reviewed. Methods: Twenty patients were women, 10 were men with a mean age of 39 years. The tumors were located in the abdominal wall (7), upper extremity (6), lower extremity (6), back (5), thoracic wall (4), head-and-neck region (1). One patient presented with multifocal tumors. Largest mean tumor diameter was 7 cm. Twenty-nine patients had surgery, 3 of which had additional radiotherapy. One patient received adjuvant antioestrogen therapy (Tamoxifen®). The surgical margins were intralesional in 6 tumors, marginal in 13 tumors and wide/compartmental in 10 tumors. One patient had radiotherapy alone. Results: Two patients died of non-tumor related causes. Sixteen patients were continuously disease free (CDF). At follow-up, all patients but 1 were free of symptoms. Thirteen patients had no evidence of disease (NED), two of which were primarily operated with debulking surgery. Six patients had mild to moderate posttreatment symptoms. One patient was alive with disease (AWD). She was operated on three times and had additional radiotherapy as well as antioestrogen therapy. At follow-up the patient had disabling symptoms. The overall recurrence rate was 44%. A less tendency for recurrence was evident in patients operated with a wide or compartmental excision. Three tumors disappeared spontaneously. Conclusions: Patients operated with a wide or compartmental margin had the least risk to develop recurrent tumor. Observation alone might be considered in selected cases. Objectives: Evaluation of tolerability of low dose chemotherapy for desmoid tumours. Methods: 10 patients with desmoid tumours (six male; four female; median age 43 years , median WHO performance score 0 [0-1]), for whom surgery was considered to be severely mutilating, were treated with chemotherapy consisting of weekly intravenous methotrexate 50 mg and vinblastine 10 mg, scheduled to be given for one year.This regimen has previously been reported as active for desmoids and to be devoid of serious toxicity. Toxicity was assessed using NCI-CTC criteria. If full doses could not be given because of side effects the dose was either reduced or the dose interval was extended, based upon the observed type of toxicity. The reasons for preliminary termination of the treatment regimen were registered. Results: No patient could complete the treatment. In all cases dose reduction, delay of dose interval or preliminary termination of the treatment was necessary. All patients had nausea varying from grade I-III, despite antiemetics. Four patients developed polyneuropathy (grade I-III), four had continuous fatigue (grade I-II), two developed leucopenia (grade II-III), two patients developed grade II-III impairment of liver function. One patient developed reversible methotrexate induced pulmonary brosis. One patient experienced a complete remission lasting 26 months, eight had stable disease, and one progressed on treatment. Six patients underwent surgery following chemotherapy. Conclusions: Our experience indicates severe long term toxicity is related to this chemotherapy. This is in sharp contrast with a previous report. We believe the regimen can not be recommended for routine use outside study protocols. Objectives: To evaluate the relationship between postoperative external beam radiation dose and local control for patients with risk factors for local recurrence after surgery and radiation. Methods: From 1961 to 1999, 804 patients with non-metastatic soft tissue sarcoma were treated with gross total surgical resection and post-operative radiation, with or without adjuvant chemotherapy. Histological sub-type was as follows: MFH, 265 patients; liposarcoma, 97; synovial sarcoma, 91; unclassi ed, 90; neurogenic sarcoma, 58; Rhabdomyosarcoma, 39; other, 164 . Surgical resection margins were positive or uncertain in 377 patients. One hundred and forty eight patients (18%) presented with locally recurrent disease after previous surgical resection. Histological grade was low/intermediate in 234 patients and high in the remaining 570 patients. Median tumor size was 5cm (range 0.5-36cm). Radiation was delivered to a median dose of 61Gy (range 36-75). Only 11 patients received doses <50Gy. Adjuvant systemic therapy was given to 215 patients. Results: At a median follow-up of 12 years, 322 patients (40%) developed disease relapse at any site. The 10-year actuarial overall and disease-free survival rates were 61% and 58%, respectively. The 10-year actuarial local, nodal and distant control rates were 79%, 96%, and 70%, respectively. Multivariate analysis con rmed an independent association between positive surgical resection margins (p<0.001), age >47 years (p=0.002), high histological grade (p=0.006), size >5cm (p=0.01), locally recurrent disease (p<0.001), postoperative radiation dose <64Gy (p<0.001) and an inferior 10-year local control rate. In three of these high-risk subgroups higher radiation dose postoperatively improved the 10-year local control rate. For patients with positive surgical resection margins radiation dose ›64Gy resulted in a 10-year local control rate of 75% compared to 55% for lesser doses (p<0.001). For patients presenting with locally recurrent disease after previous surgical treatment radiation doses ›64Gy resulted in a 10-year local control rate of 76% compared to 59% for lesser doses (p=0.05). For patients with high grade disease the same doses resulted in 10-year local control rates of 79% as compared to 74%, however this difference was of only borderline signi cance (p=0.06).
Conclusions: This radiation dose-response analysis suggests that the adverse prognostic signi cance of positive surgical resection margins and locally recurrent disease after surgical resection may be partially overcome with postoperative radiation dose in excess of 64Gy. Objectives: To assess the clinical gains predicted by use of proton beams rather than the highest technology photon beams in the radiation treatment of sarcomas of the pelvis. Methods: Complete treatment plans based on intensity modulated proton and photon methods for sarcomas at the sacrum, pubic bone/symphysis and inguinal soft tissues. The treatment plans are to account for heterogeneities in tissue densities, motion of the target and critical normal tissues during and between treatment sessions. The comparison of the treatment plans will be based upon calculated complication probabilities for the critical normal tissues for the different plans. Estimates of the maximum dose for each plan for a Grade IV complication probability of 1, 3 and 5% will be presented. Estimates will be presented of the tumor control probability for each plan for the three levels of complication probability.
Advantages Of Proton Beams
Results: The major predicted clinical gains for each of the three sites are: Site 1 sacrum, virtually no dose to the intestinal track; Site 2 pubic bone/symphysis -virtually no dose to the urinary bladder and Site 3 inguinal regional, virtually no dose to femoral head/neck. The result is marked reduction to treatment related morbidity at those normal tissues.The markedly lower doses to the intestinal tract and bladder will offer the addition gain of higher chemotherapy doses. The nal calculated probabilities will be presented in November. Conclusions: For radiation treatment of sarcomas of these three anatomic sites, proton beam technology is predicted to yield a higher proportion of patients who are rendered tumor and complication free. (ASCO 2002 (ASCO , abstract 1609 . One year after the end of accrual, 22 patients were still under protocol therapy. A total of 19 patients (70%) have responded to therapy (1CR, 18PR); 2 of these patients progressed after 261 and 323 days of treatment respectively, but were kept on treatment. Five patients had a stabilization of their disease, ongoing for 280, 371 and 391 days in 3 cases. The 3 other patients had progressive disease at the rst disease evaluation (8 weeks). The 1-year estimate (Kaplan-Meier) of progression free survival is 73% (s.e.: 9%). So far, 2 patients have died (both from progression). The 1-year survival estimate is 96% (s.e.: 4%).
Conclusions:
These results indicate that the activity of imatinib in GIST is long lasting. STBSG has subsequently randomized 946 patients in a phase III trial to compare the activity of the drug administered at 400mg/day and 400mg b.i.d. Objectives: Dermato brosarcoma protuberans (DFSP) are highly invasive dermal mesenchymal neoplasms that occasionally metastasize. Standard chemotherapy has not been effective. Activation of the platelet derived growth factor B (PDGFB) receptor, a transmembrane kinase, by aberrant expression of platelet derived growth factor B is central to the pathogenesis of DFSP. We treated a patient with unresectable, metastatic DFSP with imatinib mesylate to investigate the response of this malignancy to inhibition of the PDGFB pathway. Methods: A patient with metastatic DFSP received imatinib mesylate twice daily.Tumor response to therapy was assessed using uorodeoxyglucose-positron emission tomography, magnetic resonance imaging, immunohistochemistry and standard pathology. Results: The patient tolerated twice daily ingestion of imatinib mesylate. After two weeks of treatment, uorodeoxyglucose uptake in the DFSP fell to background levels.Tumor volume progressively shrank over four months by more than 75% allowing for complete resection of the residual mass. Histologic evaluation revealed a complete pathologic response to treatment. Adjuvant therapy with imatinib mesylate was not used. The patient remains free of tumor more than nine months after surgery. Conclusions: Imatinib mesylate appears to be highly active in DFSP when administered twice daily. The optimal duration of therapy to obtain a complete response is not known, but in this patient, four months of treatment resulted in a complete histologic response and allowed for complete resection of the residual mass. This result demonstrates that therapies targeting speci c oncogene pathways central to the pathogenesis of a neoplasm can result in dramatic therapeutic effects. Conclusions: Overall prosthetic survival (92.8%) has proven to be greater than most surgeons anticipated in the early days of limbsalvage surgery. At an average follow-up of 7 years, 67% (36/54) patients who required reoperation were able to retain their prostheses. All patients with soft tissue complications were salvaged with an average of 3 procedures, while 45% (5/11) of patients with deep infections were salvaged. Prosthetic failure due to mechanical complications diminished signi cantly from 64% (7/11) to 36% (4/11) with introduction in 1988 of modular prostheses. Meticulous attention to technique and aggressive management of soft-tissue complications leads to excellent prosthetic survival. Objectives: The role of adjuvants in preventing local recurrence following curettage of giant cell tumour of bone (GCT) remains controversial. We have reviewed our experience of curettage alone to fuel the debate. Methods: All patients treated for primary giant cell tumours of bone over a 27 year period by detailed curettage with a high speed burr were reviewed. Risk factors for local recurrence were identi ed. Results: Of 137 with previously untreated GCT of bone, 29 had a pathological fracture. Campanacci grading showed that 14 were grade I, 47 were grade II and 52 were grade III Following curettage, 26 patients (19%) developed local recurrence (LR) at a mean of 22 months. Size, site and fracture were not related to LR. For intraosseous tumours (grades I and II) the LR rate was 7% whilst for extraosseous tumours the LR rate was 29%. Of the 26 LRs, 16 had a further curettage of whom 10 were cured by one curettage and 4 following a third curettage.The success rate of curettage was 81% with one operation, 88% with two and 91% with three curettages.The mean MSTS functional score in these patients was 94%. Conclusions: The literature suggests an overall LR of 27% for curettage and 19% when an adjuvant is used. With cryotherapy an LR of 4% was achieved. Local control of GCT of bone is not yet resolved. The role of adjuvants has not been proved by the published literature and an international prospective randomized trial is recommended.
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